跳至主要内容
临床试验/ITMCTR2000003818
ITMCTR2000003818尚未招募4 期

Study on the evolution and clinical characteristics of damp-heat syndrome in diabetic coronary heart disease

Affiliated Hospital of Shaanxi University of Chinese M0 个研究点开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 80(—)
性别
All

入选标准

  • (1) Meet the diagnostic criteria of Western medicine for type 2 diabetes, and disease course >=6 months;
  • Meet the diagnostic criteria of stable coronary artery disease, CCS grade >=II in the screening phase of stable angina;
  • (3) Meet the TCM diagnostic criteria of damp-heat and collaterals blocking syndrome;
  • (4) Aged 40-80 years, both male and female;
  • (5) Screening period HbA1c 4.0 to 8.0%;
  • (6) Volunteer, understand, and sign informed consent.

排除标准

  • 1. Exclusion indicators related to disease status:
  • (1) T1DM, secondary diabetes or failure to specify which type of diabetes is the first diagnosis;
  • (2) Those who experienced severe hypoglycemic events, experienced ketoacidosis, or hyperosmolar coma within 3 months;
  • (3) Those who had acute coronary syndrome (ACS) within 3 months;
  • (4) New cerebrovascular accidents within 6 months;
  • (5) Patients with uncontrolled severe heart failure (NYHA grade >=III), severe arrhythmia and other heart diseases;
  • 2. TCM syndrome type clinical performance exclusion indicators:
  • (6) Patients with TCM syndromes that have obvious manifestations of cold syndrome, symptoms: fear of cold, cold limbs, urine clear long, etc.;
  • 3. Exclusion indicators related to previous medication:
  • (7) Those who have received other traditional Chinese medicine within 14 days before administration for the treatment of damp-heat obstruction syndrome, diabetes, or coronary heart disease;
  • (8) Allergic constitution or previous allergy to multiple drugs, or allergic to the ingredients in the study drugs;
  • 4. Exclusion indicators related to the health status of patients:
  • (9) Uncontrolled hypertension, systolic blood pressure (SBP) >=180mmHg and/or diastolic blood pressure (DBP) >110 mmHg; or SBP <90 mmHg and/or DBP <50 mmHg;
  • (10) Patients with severe liver and kidney dysfunction (including patients undergoing dialysis) and active liver disease (including primary biliary cirrhosis and unexplained persistent liver dysfunction);
  • (11) Patients with comorbidities that may interfere the efficacy or safety assessment: such as cardiovascular, respiratory, gastrointestinal, pancreatic, pancreatic, liver, kidney, neuropsychiatric, and blood systems ( Such as hematological tumors, hemolytic anemia, sickle cell disease, etc.), immune system diseases;
  • (12) Patients with serious systemic diseases such as malignant tumors before screening;
  • 5. Conventional exclusion indicators:
  • (13) Females who are pregnant or lactating, preparing for pregnancy during the trial, or have a positive pregnancy test at the time of admission;
  • (14) Participation in other clinical studies within 3 months.

研究者

发起方
Affiliated Hospital of Shaanxi University of Chinese M

相似试验